<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141079">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01702883</url>
  </required_header>
  <id_info>
    <org_study_id>20789</org_study_id>
    <nct_id>NCT01702883</nct_id>
  </id_info>
  <brief_title>The Medication Experience Study</brief_title>
  <official_title>Using an Internet Survey to Improve Patient Adherence in Chronic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether participation in an Internet-based
      intervention helps improve medication use.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>The primary measure will be adherence as measured by pharmacy refills in each group.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1112</enrollment>
  <condition>Hypertension</condition>
  <condition>Elevated Cholesterol</condition>
  <condition>Diabetes</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Randomization occurs after enrollment survey has been completed. This group will not receive the internet intervention for the twelve months. They will be asked to complete the final survey.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomization occurs after enrollment survey has been completed. Upon secondary randomization at week eight, this group will continue to receive weekly internet surveys for the entire twelve months. They will be asked to complete the final survey.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomization occurs after enrollment survey has been completed. This group will complete weekly internet surveys for eight weeks. Upon secondary randomization at week eight, this group will begin to receive monthly internet surveys. They will be asked to complete the final survey.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomization occurs after enrollment survey has been completed. This group will complete weekly internet surveys for eight weeks. Upon secondary randomization at week eight, the group will not receive any more internet surveys. They will be asked to complete the final survey.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Internet Survey</intervention_name>
    <description>prompt to complete internet survey</description>
    <arm_group_label>Intervention Group A</arm_group_label>
    <arm_group_label>Intervention Group B</arm_group_label>
    <arm_group_label>Intervention Group C</arm_group_label>
    <other_name>internet surveys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any male or female 18 years or older, filling prescriptions for oral medications for
             hypertension, high cholesterol, diabetes, or depression at the Downtown Health Plaza,
             Piedmont Plaza, or Cancer Center Pharmacies.

        Exclusion Criteria:

          -  Inability to complete Internet surveys due to inadequate Internet access, not
             understanding a survey written in English, or lack of computer skills.

          -  Patient does not intend to continue using the same WFBMC-affiliated pharmacy for the
             next 12 months.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve R Feldman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Irma M Richardson, MHA</last_name>
    <phone>336-716-2903</phone>
    <email>irichard@wakehealth.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irma M Richardson, MHA</last_name>
      <phone>336-716-2903</phone>
      <email>irichard@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>October 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wake Forest School of Medicine</investigator_affiliation>
    <investigator_full_name>Steven R. Feldman</investigator_full_name>
    <investigator_title>Professor of Dermatology</investigator_title>
  </responsible_party>
  <keyword>prescriptions</keyword>
  <keyword>hypertension</keyword>
  <keyword>high cholesterol</keyword>
  <keyword>diabetes</keyword>
  <keyword>depression</keyword>
  <keyword>adherence</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
